menu

The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy

close
0.50 credits
30 Minutes
The Evolving Landscape of Chronic Lymphocytic Leukemia: Selecting and Managing Targeted Therapy
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.

    In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.

  • Target Audience

    This activity is designed to meet the educational needs of hematologists-oncologists, nurses, nurse practitioners, and physician assistants.

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • DESCRIBE efficacy and safety data for approved targeted therapies for patients with CLL in the front-line and R/R settings
    • EVALUATE clinical trial data surrounding safety and efficacy of investigational targeted therapies for CLL
    • SELECT targeted therapy for patients with newly diagnosed and R/R CLL incorporating recent evidence and best practice strategies
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Johns Hopkins University School of Medicine and Spire Learning. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    The Johns Hopkins School of Medicine designates this activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Johns Hopkins School of Medicine and Spire Learning.

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Policy on Presenter and Provider Disclosure

    It is the policy of the Johns Hopkins School of Medicine that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

  • Disclosure of Conflicts of Interest

    As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

    FACULTY:
    Nina Delaney Wagner-Johnston, MD
    Associate Professor of Oncology
    Johns Hopkins University School of Medicine
    Director, Lymphoma Drug Development
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 
    Baltimore, MD

    Disclosure Statement:
    Consultant: Epizyme; Grünenthal; Seagen Inc
    Advisory Board: Epizyme; Grünenthal; Seagen Inc

    Seema A. Bhat, MD
    Associate Professor
    Division of Hematology
    Department of Internal Medicine
    The Ohio State University Comprehensive Cancer Center
    Columbus, OH

    Disclosure Statement:
    Consultant: AstraZeneca plc; BeiGene Co, Ltd

    EDUCATIONAL PLANNING COMMITTEE

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Spire Learning
    Chad Thompson and Mairead Early: No relevant financial relationships with any commercial interests.

    Christopher Washburn, PhD, discloses the following:
    Employee (spouse): Janssen Pharmaceuticals, Inc

    Andrew D. Bowser, ELS, CHCP, discloses the following:
    Employee (spouse): ALK; CSL Behring; Pharming; Takeda 

    Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

  • Johns Hopkins Statement of Responsibility

    The Johns Hopkins School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

  • Internet CME Policy

    The Office of Continuing Medical Education (OCME) at the Johns Hopkins School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins School of Medicine OCME maintains its internet site as an information resource and service for physicians, other health professionals and the public. OCME at the Johns Hopkins School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins School of Medicine CME program. CME collects only the information necessary to provide you with the services that you request.

  • Disclaimer

    The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

  • Off-Label Statement

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Johns Hopkins School of Medicine and Spire Learning do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Privacy Policy

    Spire Learning Privacy Policy:
    Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

    Collection and use of your personal information
    The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.

    Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed internet connection is recommended (DSL/Cable/Fiber). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Confidentiality Disclaimer for CME Activity Participants

    I certify that I am participating in this Johns Hopkins School of Medicine activity for CME-accredited training and/or educational purposes.

    I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

    I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

    I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality.
    The contact information is: 
    Johns Hopkins Privacy Officer, telephone: 410-614-9900, e-mail: HIPAA@jhmi.edu.

    “The Office of Continuing Medical Education at the Johns Hopkins School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

    For CME questions, please contact the CME Office 410-955-2959 or email cmenet@jhmi.edu.
    For CME Certificates, please call 410-502-9636.

    Johns Hopkins School of Medicine
    Office of Continuing Medical Education
    720 Rutland Avenue/ Turner 20
    Baltimore, Maryland 21205-2195
    Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
    (Updated 4/09 and 3/14)

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.

    In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.

  • Target Audience

    This activity is designed to meet the educational needs of hematologists-oncologists, nurses, nurse practitioners, and physician assistants.

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • DESCRIBE efficacy and safety data for approved targeted therapies for patients with CLL in the front-line and R/R settings
    • EVALUATE clinical trial data surrounding safety and efficacy of investigational targeted therapies for CLL
    • SELECT targeted therapy for patients with newly diagnosed and R/R CLL incorporating recent evidence and best practice strategies
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Johns Hopkins University School of Medicine and Spire Learning. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    The Johns Hopkins School of Medicine designates this activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Johns Hopkins School of Medicine and Spire Learning.

  • Commercial Support

    This activity is supported by an educational grant from Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • Policy on Presenter and Provider Disclosure

    It is the policy of the Johns Hopkins School of Medicine that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

  • Disclosure of Conflicts of Interest

    As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME. The following relationships have been reported for this activity:

    FACULTY:
    Nina Delaney Wagner-Johnston, MD
    Associate Professor of Oncology
    Johns Hopkins University School of Medicine
    Director, Lymphoma Drug Development
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 
    Baltimore, MD

    Disclosure Statement:
    Consultant: Epizyme; Grünenthal; Seagen Inc
    Advisory Board: Epizyme; Grünenthal; Seagen Inc

    Seema A. Bhat, MD
    Associate Professor
    Division of Hematology
    Department of Internal Medicine
    The Ohio State University Comprehensive Cancer Center
    Columbus, OH

    Disclosure Statement:
    Consultant: AstraZeneca plc; BeiGene Co, Ltd

    EDUCATIONAL PLANNING COMMITTEE

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Spire Learning
    Chad Thompson and Mairead Early: No relevant financial relationships with any commercial interests.

    Christopher Washburn, PhD, discloses the following:
    Employee (spouse): Janssen Pharmaceuticals, Inc

    Andrew D. Bowser, ELS, CHCP, discloses the following:
    Employee (spouse): ALK; CSL Behring; Pharming; Takeda 

    Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

  • Johns Hopkins Statement of Responsibility

    The Johns Hopkins School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

  • Internet CME Policy

    The Office of Continuing Medical Education (OCME) at the Johns Hopkins School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins School of Medicine OCME maintains its internet site as an information resource and service for physicians, other health professionals and the public. OCME at the Johns Hopkins School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins School of Medicine CME program. CME collects only the information necessary to provide you with the services that you request.

  • Disclaimer

    The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

  • Off-Label Statement

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Johns Hopkins School of Medicine and Spire Learning do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Privacy Policy

    Spire Learning Privacy Policy:
    Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.

    Collection and use of your personal information
    The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.

    Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed internet connection is recommended (DSL/Cable/Fiber). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Confidentiality Disclaimer for CME Activity Participants

    I certify that I am participating in this Johns Hopkins School of Medicine activity for CME-accredited training and/or educational purposes.

    I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.

    I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.

    I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality.
    The contact information is: 
    Johns Hopkins Privacy Officer, telephone: 410-614-9900, e-mail: HIPAA@jhmi.edu.

    “The Office of Continuing Medical Education at the Johns Hopkins School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”

    For CME questions, please contact the CME Office 410-955-2959 or email cmenet@jhmi.edu.
    For CME Certificates, please call 410-502-9636.

    Johns Hopkins School of Medicine
    Office of Continuing Medical Education
    720 Rutland Avenue/ Turner 20
    Baltimore, Maryland 21205-2195
    Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03)
    (Updated 4/09 and 3/14)

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 8/1/21